Scopus Publication Detail
The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in Scopus. This abstract is what is used to create the fingerprint of the publication.
Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines
Yingming Li; Siu Chiu Chan; Lucas J. Brand; Tae Hyun Hwang; Kevin A.T. Silverstein; Scott M. Dehm(Profiled Author: Tae Hyun Hwang)
Cancer Research. 2013;73(2):483-489.Abstract
Persistent androgen receptor (AR) transcriptional activity underlies resistance to AR-targeted therapy and progression to lethal castration-resistant prostate cancer (CRPC). Recent success in retargeting persistent AR activity with next generation androgen/AR axis inhibitors such as enzalutamide (MDV3100) has validated AR as a master regulator during all stages of disease progression. However, resistance to next generation AR inhibitors limits therapeutic efficacy for many patients. One emerging mechanism of CRPC progression is AR gene rearrangement, promoting synthesis of constitutively active truncated AR splice variants (AR-V) that lack the AR ligand-binding domain. In this study, we show that cells with AR gene rearrangements expressing both full-length and AR-Vs are androgen independent and enzalutamide resistant. However, selective knock-down of AR-V expression inhibited androgen-independent growth and restored responsiveness to androgens and antiandrogens. In heterogeneous cell populations, AR gene rearrangements marked individual AR-V-dependent cells that were resistant to enzalutamide. Gene expression profiling following knock-down of full-length AR or AR-Vs showed that AR-Vs drive resistance to AR-targeted therapy by functioning as constitutive and independent effectors of the androgen/AR transcriptional program. Further, mitotic genes deemed previously to be unique ARV targets were found to be biphasic targets associated with a proliferative level of signaling output from either ARVs or androgen-stimulated AR. Overall, these studies highlight AR-Vs as key mediators of persistent AR signaling and resistance to the current arsenal of conventional and next generation AR-directed therapies, advancing the concept of AR-Vs as therapeutic targets in advanced disease. © 2012 AACR.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Kevin D. Courtney; Mary-Ellen TaplinCurrent Opinion in Oncology. 2012;24(3):272-277.
Nima SharifiExpert Opinion on Investigational Drugs. 2010;19(7):837-846.
Michael D. Nyquist; Yingming Li; Tae Hyun Hwang; Luke S. Manlove; Robert L. Vessella; Kevin A.T. Silverstein; Daniel F. Voytas; Scott M. DehmProceedings of the National Academy of Sciences of the United States of America. 2013;110(43):17492-17497.
Appears in this Document